PEN - PENUMBRA INC （）

Penumbra has demonstrated its capacity to unlock long-term shareholder value. Click here to find out why PEN stock is a Buy.

ALAMEDA, Calif., April 4, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023 at 4:30 PM Eastern Time. A press release with first quarter 2023…

According to Benzinga Pro, during Q4, Penumbra (NYSE: PEN ) earned $3.88 million, a 270.72% increase from the preceding quarter. Penumbra also posted a total of $221.22 million in sales, a 3.53% increase since Q3. In Q3, Penumbra brought in $213.68 million in sales but lost $2.27 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative … Full story available on Benzinga.com

Penumbra, Inc. - Consensus Indicates Potential -2.1% Downside

https://www.investing.com/news/assorted/penumbra-inc-files-mixed-shelf-432SI-3013489

Penumbra Inc (PEN) shares closed today at 0.4% below its 52 week high of $268.49, giving the company a market cap of $10B. The stock is currently up 20.1% year-to-date, up 20.3% over the past 12 months, and up 182.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 28.4% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 311.6% The company's stock price performance over the past 12 months beats the peer average by -212.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

https://www.investing.com/news/pro/penumbra-pt-raised-to-297-at-deutsche-bank-432SI-2997179

Penumbra Inc (PEN) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $9B. The stock is currently up 16.7% year-to-date, up 18.1% over the past 12 months, and up 175.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 57.9% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 294.7% The company's stock price performance over the past 12 months beats the peer average by -196.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

NEW YORK (AP) — Before the artificial intelligence tool ChatGPT was unleashed into the world, the novelist Robin Sloan was testing a similar AI writing assistant built by researchers at Google. It didn’t take long for Sloan, author of the bestseller “Mr. Penumbra’s 24-hour Bookstore,” to realize that the technology was of little use to […]

ALAMEDA, Calif., Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023 at 4:30 PM Eastern Time. A press release…

NEW YORK (AP) — Before the artificial intelligence tool ChatGPT was unleashed into the world, the novelist Robin Sloan was testing a similar AI writing assistant built by researchers at Google. It didn’t take long for Sloan, author of the bestseller “Mr. Penumbra’s 24-hour Bookstore,” to realize that the technology was of little use to […]

ALAMEDA, Calif., Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023 at 4:30 PM Eastern Time. A press release…

Penumbra found using ticker (PEN) now have 10 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The range between the high target price and low target price is between 270 and 195 calculating the mean target price we have 246. With the stocks previous close at 239.51 this now indicates there is a potential upside of 2.7%. The day 50 moving average is 211.43 and the 200 day moving average is 174.74. The market capitalisation for the company is $9,102m. You can visit the company''s website by visiting: https://www.penumbrainc.com [stock_market_widget type="chart" template="basic" color="green" assets="PEN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,349m based on the market concensus. Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.

NEW YORK, 2023-Jan-20 — /EPR Network/ — “Neurovascular Devices/ Interventional Neurology Market Report, 2022 to 2030 Neurovascular Devices/ Interventional Neurology Market study performed by market [read full press release…]

Wells Fargo said that based on early feedback from physicians, the recent launch of Penumbra''s (PEN) Lightning Flash mechanical thrombectomy system will boost growth.